Cross Labeling Oncology Drugs in Combination Regimens
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 2, 2022
November 8, 2022
d50f604f-4d0f-4aaa-a83a-b8a75b4a71ee
Related Documents
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 28, 2022Office of the Commissioner
Inclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry
Guidance DocumentMarch 2, 2022Office of the Commissioner
Male Breast Cancer: Developing Drugs for Treatment: Guidance for Industry
Guidance DocumentAugust 12, 2020Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.